Vivoryon Therapeutics N.V.
VVY.AS · AMS
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | €38,149 | €51,697 | €50,048 | €199,367 |
| - Cash | €4,837 | €9,365 | €15,272 | €18,562 |
| + Debt | €72 | €102 | €10 | €38 |
| Enterprise Value | €33,384 | €42,434 | €34,786 | €180,843 |
| Revenue | €0 | €0 | €0 | -€3,620 |
| % Growth | – | – | 100% | – |
| Gross Profit | -€73 | -€74 | -€73 | -€4,145 |
| % Margin | – | – | – | 114.5% |
| EBITDA | -€5,480 | -€6,855 | -€13,763 | -€17,502 |
| % Margin | – | – | – | 483.5% |
| Net Income | -€5,473 | -€7,009 | -€13,559 | -€17,626 |
| % Margin | – | – | – | 486.9% |
| EPS Diluted | -0.21 | -0.27 | -0.52 | -0.72 |
| % Growth | 22.2% | 48.1% | 27.8% | – |
| Operating Cash Flow | -€4,496 | -€5,874 | -€13,300 | -€1,258 |
| Capital Expenditures | -€4 | -€2 | €0 | -€5 |
| Free Cash Flow | -€4,500 | -€5,876 | -€13,300 | -€1,263 |